Early Phase 1 N=6 Investigation of Female Reproductive Hormone Dynamics During Adolescence
Menstruation Disturbances
Primary: Ovulation in Cycle 2 — 3; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=104 Quality of Life in Premenopausal Women With Heavy Menstrual Bleeding
Heavy Menstrual Bleeding
Primary: Hot Flush Frequency Total Score (HFRS) Change — 9.3; 8.8; 12.7 score on a scale
N/A N=4 Relationship Between the Menstrual Cycle and Heart Disease in Women
Coronary Heart Disease
Primary: Total to HDL Cholesterol Ratio — 0.146; 0.148; -0.89 Total to HDL Cholesterol Ratio
Phase 3 N=45 Cinnamon Extract on Menstrual Cycles in PolyCystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome
Primary: Number of Menses During the Six Month Study Period. — .42; .42; .75; .25 Number of menstrual cycles per month
N/A N=1,000 Duphaston in Cycle Regularization: A Post-marketing, Prospective, Multicenter, Observational Study
Irregular Menstrual Cycle
Primary: Percentage of Patients Reporting a Regular Cycle — 96.7 percentage of participants
N/A N=999 Treatment Regimen in Menstrual Cycle Regularization and Persistence in Routine Clinical Practice in Russia, Ukraine, Kazakhstan and Uzbekistan
Irregular Menstrual Cycle
Primary: Number of Patients Received Dydrogesterone Therapy Cycles (by Cycle Number) — 1; 4; 269; 66 participants
N/A N=38 Mirena and Estrogen for Control of Perimenopause Symptoms and Ovulation Suppression
Menopausal and Other Perimenopausal Disorders
Primary: Hot Flashes — 10.3; 7.944 scores on a scale
Phase 3 N=105 Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding
Menorrhagia
Primary: Number of Participants With Successful Treatment of Heavy Menstrual Bleeding — 81; 83 Participants
Phase 3 N=165 Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine System (IUS)
Menorrhagia
Primary: The Change in Absolute Value From Baseline Menstrual Blood Loss (MBL) to the End-of-study MBL (Cycle 6) — -128.78; -17.7 milliliter (mL) — p=<0.001
Phase 4 N=32 Tranexamic Acid in Adolescents With Heavy Menstrual Bleeding
Heavy Menstrual Bleeding
Primary: Change From Baseline Menses for Participant Perceived Blood Loss — 3; 1.9 score on a scale
Phase 4 N=48 DMPA & High Dose Oral Progestin (MPA) Tablets in Outpatient Treatment of Acute Excessive Vaginal Bleeding
Dysfunctional Uterine Bleeding
Primary: Cessation of Bleeding Within 5 Days — 48 participants
N/A N=25 Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
Polycystic Ovary Syndrome · Hyperandrogenism
Primary: Change in Progesterone Sensitivity Index Before and After Metformin Treatment. — -4.12; -4.29 % change in LH pulses/day 7 P4 level
Phase 4 N=34 Estrogen Variability and Irritability During the Menopause Transition
Menopause · Irritable Mood
Primary: Mean IDAS Ill Temper Scale Score Over Time — 6.19; 6.02 score on a scale — p=0.09
Phase 1 N=20 A Treatment Study for Premenstrual Syndrome (PMS)
Premenstrual Syndrome · Menstruation Disturbances
Primary: Mean Beck Depression Inventory Score — 2.6; 3.0; 5.3; 3.6 score on a scale
N/A N=21 A Two-Phase Clinical Study of the Minerva AURORA Ablation System
Menorrhagia Due to Benign Causes
Primary: Reduction in Menstrual Blood Loss to Normal Levels at 12-months — 20 participants
Phase 3 N=507 Effect on Primary Dysmenorrhea
Primary Dysmenorrhea
Primary: Change Between Baseline Evaluation Period and Treatment Evaluation Period in the Number of Days With Dysmenorrheic Pain — -4.6; -4.2 Days
Phase 4 N=46 Unique Effects of Perimenstrual Estradiol or Progesterone Supplementation on Perimenstrual Suicidality
Suicidal Ideation
Primary: Cyclical Change in Suicidal Ideation (SI) Severity — -.22; -.05; .25 units on a scale — p=.002
Phase 4 N=67 Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD)
Premenstrual Dysphoric Disorder
Primary: Pre-Post Change in Premenstrual Symptom Severity — 1.93; 1.73; 1.64 units on a scale
N/A N=60 Dysregulation of FSH in Obesity: Functional and Statistical Analysis
Obesity · Fertility
Primary: Difference Between Peak Inhibin B — 100.8; 38.8 picograms/mL
Phase 4 N=28 Copper IUD Treatment Observation Study
Menorrhagia
Primary: Mean Days of Bleeding and Spotting, Spotting Only and Bleeding Only for the 84 Day Treatment Cycles and Last 28 Day Post-treatment Cycle — 29.2; 23.0; 9.3; 9.6 days…
N/A N=79 Tracking IUD Bleeding Experiences: An Evaluation of Bleeding Profiles in New Intrauterine Device Users
Intrauterine Devices, Copper · Metrorrhagia · Menstruation
Primary: Evaluate Changes in Bleeding Duration Among Women Initiating the Copper T380 IUD During the 90 Days Prior to Initiation Compared to Two 90 Periods After IUD Insertion…
Phase 3 N=121 Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes
Exercise-related Amenorrhea
Primary: Change in Lumbar Bone Mineral Density — 0.025; 0.008; 0.012 g/cm^2 — p=0.039
Phase 2 N=92 The Effects of Reproductive Hormones on Mood and Behavior
Healthy Volunteers
Primary: Mean Beck Depression Inventory Score — 1.4; 1; 1.1 Units on a scale
N/A N=68 Study to Evaluate the Efficacy of Elix's Cycle Balance and Its Impact on PMS and Menstrual Symptoms
PMS · Menstrual Pain
Primary: Relief From Premenstrual Cramps [Time Frame: Baseline to 3 Months] — 4.41; 3.48; 3.12; 2.72 score on a scale — p=<0.001
N/A N=11 The Effects of a Prostaglandin Inhibitor on Ovulation and the Menstrual Cycle
Ovulation (Follicular Rupture Yes/no) · Menstrual Cycles (Total Length, Bleeding Days) · Gonadotropin and Ovarian Hormone Levels (FSH, LH, E2, P)
Primary: Menstrual Cycle Length — 28.5; 27.2 Days
N/A N=129 Premenstrual Hormonal and Affective State Evaluation (PHASE) Project
Premenstrual Dysphoric Disorder
Primary: Hormone Analysis — 70.7; 57.8; 114; 97.3 ng/mL
Phase 4 N=67 Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia
Menorrhagia
Primary: Menstrual Blood Loss (MBL) as Measured by Pictorial Blood Loss Assessment Chart (PBLAC). — 15; 0 units on a scale — p=0.003
Phase 3 N=190 Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding
Metrorrhagia
Primary: Proportion of Participants With no Dysfunctional Uterine Bleeding (DUB) Symptoms — 0.292; 0.029 Proportion of participants — p=< 0.0001
Phase 4 N=30 Effect of Perimenstrual Ovarian Steroid Supplementation on Perimenstrual Suicidality
Suicidal Ideation
Primary: Perimenstrual Change in Self-Injurious Thoughts and Behaviors Interview (SITBI) Suicidal Ideation Score — -.05; .35 units on a scale — p=.012
Phase 3 N=231 Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding
Metrorrhagia
Primary: Proportion of Participants With no Dysfunctional Uterine Bleeding (DUB) Symptoms — 0.295; 0.012 Proportion of participants — p=< 0.0001